Sedana Medical AB (publ) (SEDANA.ST)
SEK 15.94
(-4.78%)
SEK 15.94
(-4.78%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.01 Million SEK | -71.7% |
| 2022 | 3.57 Million SEK | -22.96% |
| 2021 | 4.64 Million SEK | -12.81% |
| 2020 | 5.32 Million SEK | 543.0% |
| 2019 | 828 Thousand SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 4.88 Million SEK | -10.11% |
| 2015 | 5.42 Million SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 4.22 Million SEK | 0.0% |
| 2024 Q1 | 1.28 Million SEK | 0.0% |
| 2024 Q3 | - SEK | 0.0% |
| 2023 Q3 | 1.13 Million SEK | -20.98% |
| 2023 Q4 | 1.01 Million SEK | -10.44% |
| 2023 FY | 1.01 Million SEK | -71.7% |
| 2023 Q1 | 2.53 Million SEK | -29.17% |
| 2023 Q2 | 1.43 Million SEK | -43.55% |
| 2022 FY | 3.57 Million SEK | -22.96% |
| 2022 Q2 | 4.48 Million SEK | -11.27% |
| 2022 Q3 | 3.68 Million SEK | -17.93% |
| 2022 Q4 | 3.57 Million SEK | -2.93% |
| 2022 Q1 | 5.05 Million SEK | 8.98% |
| 2021 Q1 | 5.22 Million SEK | -1.88% |
| 2021 Q2 | 5.41 Million SEK | 3.64% |
| 2021 FY | 4.64 Million SEK | -12.81% |
| 2021 Q4 | 4.64 Million SEK | -7.92% |
| 2021 Q3 | 5.04 Million SEK | -6.89% |
| 2020 Q1 | - SEK | -100.0% |
| 2020 FY | 5.32 Million SEK | 543.0% |
| 2020 Q4 | 5.32 Million SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 Q4 | 828 Thousand SEK | 0.0% |
| 2019 FY | 828 Thousand SEK | 0.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q4 | 1.1 Million SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q3 | 179.95 Thousand SEK | -25.0% |
| 2017 Q2 | 239.94 Thousand SEK | -94.99% |
| 2017 FY | - SEK | -100.0% |
| 2017 Q4 | - SEK | -100.0% |
| 2017 Q1 | 4.79 Million SEK | -1.84% |
| 2016 Q4 | 4.88 Million SEK | 0.0% |
| 2016 FY | 4.88 Million SEK | -10.11% |
| 2015 FY | 5.42 Million SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.931% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.931% |
| Arcoma AB | 1.92 Million SEK | 47.483% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 97.608% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.942% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 98.246% |
| CellaVision AB (publ) | 28.66 Million SEK | 96.469% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -353.812% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | 42.27% |
| Duearity AB (publ) | 2.94 Million SEK | 65.578% |
| Dignitana AB (publ) | 6.07 Million SEK | 83.347% |
| Episurf Medical AB (publ) | 2.3 Million SEK | 56.0% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.974% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 84.07% |
| Iconovo AB (publ) | 4.9 Million SEK | 79.376% |
| Integrum AB (publ) | 4.84 Million SEK | 79.111% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -391.205% |
| Mentice AB (publ) | 2.14 Million SEK | 52.799% |
| OssDsign AB (publ) | 214 Thousand SEK | -372.897% |
| Paxman AB (publ) | 2.53 Million SEK | 60.032% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | 66.312% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 75.784% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 94.73% |
| Senzime AB (publ) | 8.57 Million SEK | 88.202% |
| SpectraCure AB (publ) | 4.39 Million SEK | 76.984% |
| Stille AB | 38.06 Million SEK | 97.341% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.946% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 95.219% |